Email Chinese


I-Mab Biopharma was established through a merger of Third Venture Biopharma and Tasgen in 2017, aiming to develop innovative biologics in the areas of immuno-oncology and autoimmune disease for the global markets, including China;
Management team has combined and extensive global and domestic pharma leadership experiences in innovative drug development, covering discovery, CMC, pre-clinical development, regulatory and clinical development expertise;
Current pipeline is composed of 12 projects in two portfolios, i.e. “In China for Global” and “In China for China”. It includes 3 clinical assets (1 Ph 1 and 2 Ph 2 ready assets) and 6-7 innovative assets at CMC or pre-clinical development stage with China and US clinical development plans;
R&D model combines effectively in-house R&D core capabilities in discovery, CMC, pre-clinical and clinical development with preferred CROs of global standards, e.g. Wuxi Biologics, Covance, Mabplex, Tigermed through strategic partnerships;
Current shareholders include C-Bridge/I-Bridge Capital, Management team, Genexine, Tasly Pharmaceuticals, Simcere Pharmaceuticals, TigerMed, Partners Investment, Qianhai Capital, Anlong Capital etc. Series B financing of $150 million was completed in May 2017.


  • 2018 / 9 /20

    I-Mab Wins Frost& Sullivan “2018 Best R&D Innovator Award (Biopharma Category)”

    I-Mab Biopharma ("I-Mab") announced today that it has been recognized by Forest & Sullivan, the global leading growth consulting company as well as the biggest growth consulting company in China, with... Read More >

  • I-Mab Wins Frost& Sullivan “2018 Best R&D Innovator Award (Biopharma Category)”
    I-Mab’s Announces China Clinical Trial Approval of Long-acting hGLP-1 To Treat Type 2 Diabetes
    I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

    Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com